ORB-021

· Orionis Biosciences Inc

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ORB-021, covering 2026-02-10 to 2026-02-10. Get the full timeline:

Most recent: Clinical Trial Update: ORB-021 In Patients With Advanced Solid Tumors [Phase 1]